Leerink Swann Reiterates $67.00 Price Target for EXACT Sciences (EXAS)

EXACT Sciences (NASDAQ:EXAS) has been assigned a $67.00 price target by analysts at Leerink Swann in a research report issued on Friday. The firm currently has a “buy” rating on the medical research company’s stock. Leerink Swann’s target price would suggest a potential upside of 45.97% from the company’s previous close. Leerink Swann also issued estimates for EXACT Sciences’ Q4 2017 earnings at ($0.25) EPS, FY2017 earnings at ($1.06) EPS, Q1 2018 earnings at ($0.25) EPS, Q2 2018 earnings at ($0.20) EPS, Q4 2018 earnings at ($0.08) EPS, FY2018 earnings at ($0.67) EPS and FY2019 earnings at $0.29 EPS.

EXAS has been the subject of a number of other reports. Zacks Investment Research upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a report on Tuesday, January 16th. Bank of America set a $56.00 target price on shares of EXACT Sciences and gave the stock a “buy” rating in a report on Thursday, October 19th. Canaccord Genuity upgraded shares of EXACT Sciences to a “buy” rating and set a $60.00 target price for the company in a report on Tuesday, October 31st. BidaskClub downgraded shares of EXACT Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Finally, William Blair reiterated a “buy” rating on shares of EXACT Sciences in a report on Tuesday, January 2nd. Eight investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. EXACT Sciences currently has a consensus rating of “Buy” and a consensus price target of $52.84.

EXACT Sciences (EXAS) opened at $45.90 on Friday. The company has a market cap of $5,495.61, a PE ratio of -39.57 and a beta of 0.58. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01. EXACT Sciences has a fifty-two week low of $18.30 and a fifty-two week high of $63.60.

In other news, insider Kevin T. Conroy sold 134,057 shares of the business’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $59.50, for a total transaction of $7,976,391.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP D Scott Coward sold 1,665 shares of the business’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $52.54, for a total value of $87,479.10. Following the sale, the senior vice president now owns 37,558 shares in the company, valued at approximately $1,973,297.32. The disclosure for this sale can be found here. Insiders have sold 662,694 shares of company stock worth $35,934,015 in the last 90 days. Insiders own 4.00% of the company’s stock.

Several hedge funds have recently modified their holdings of EXAS. New York State Common Retirement Fund grew its stake in shares of EXACT Sciences by 8.9% during the second quarter. New York State Common Retirement Fund now owns 156,741 shares of the medical research company’s stock worth $5,544,000 after acquiring an additional 12,821 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in EXACT Sciences in the second quarter valued at approximately $217,000. FMR LLC boosted its position in EXACT Sciences by 32.7% in the second quarter. FMR LLC now owns 2,318,269 shares of the medical research company’s stock valued at $81,997,000 after buying an additional 571,796 shares during the last quarter. California Public Employees Retirement System boosted its position in EXACT Sciences by 5.9% in the second quarter. California Public Employees Retirement System now owns 185,100 shares of the medical research company’s stock valued at $6,547,000 after buying an additional 10,300 shares during the last quarter. Finally, Advisor Group Inc. boosted its position in EXACT Sciences by 0.8% in the second quarter. Advisor Group Inc. now owns 7,866 shares of the medical research company’s stock valued at $270,000 after buying an additional 65 shares during the last quarter. Institutional investors and hedge funds own 82.32% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/02/11/leerink-swann-reiterates-67-00-price-target-for-exact-sciences-exas.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit